Hemophilia: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
== Background == | == Background == | ||
*Two types (clinically indistinguishable): | |||
**Hemophilia A: Factor VIII deficiency | *Two types (clinically indistinguishable): | ||
**Hemophilia B: Factor IX deficiency | **Hemophilia A: Factor VIII deficiency | ||
*Substantial proportion of both types arise from spontaneous mutations | **Hemophilia B: Factor IX deficiency | ||
*X-linked disorders (overwhelmingly a disease of men) | *Substantial proportion of both types arise from spontaneous mutations | ||
*ICH is most common cause of hemorrhagic death | *X-linked disorders (overwhelmingly a disease of men) | ||
* | *ICH is most common cause of hemorrhagic death | ||
*Do not give NSAIDs or IM injections | |||
*Avoid invasive procedures (e.g. central lines, LP (unless give factor replacement therapy)) | |||
*Consult hematology if pt has h/o inhibitors | *Consult hematology if pt has h/o inhibitors | ||
==Clinical Features== | == Clinical Features == | ||
#Hemarthroses | |||
##Leads to joint destruction and chronic arthropathy if not adequately treated | #Hemarthroses | ||
#Hematomas | ##Leads to joint destruction and chronic arthropathy if not adequately treated | ||
##Bleeding into soft tissues or muscle | ##Pts can reliably report when bleeding is occurring | ||
###Neck (airway compromise) | #Hematomas | ||
###Limbs (compartment syndromes) | ##Bleeding into soft tissues or muscle | ||
###Eye (retro-orbital hematoma) | ###Neck (airway compromise) | ||
###Spine (epidural hematoma) | ###Limbs (compartment syndromes) | ||
###Retroperitoneum (iliopsoas bleeds and massive blood loss) | ###Eye (retro-orbital hematoma) | ||
#Mucocutaneous bleeding | ###Spine (epidural hematoma) | ||
##Spontaneous bleeding uncommon from oropharynx, GI tract, epistaxis, or hemoptysis | ###Retroperitoneum (iliopsoas bleeds and massive blood loss) | ||
#CNS | #Mucocutaneous bleeding | ||
##Intracranial bleeding is most common cause of hemorrhagic death | ##Spontaneous bleeding uncommon from oropharynx, GI tract, epistaxis, or hemoptysis | ||
#CNS | |||
##Intracranial bleeding is most common cause of hemorrhagic death | |||
##Subdural hematomas occur spontaneously or with minimal trauma | ##Subdural hematomas occur spontaneously or with minimal trauma | ||
#Hematuria | #Hematuria | ||
##Common, usually not serious, source is rarely found | ##Common, usually not serious, source is rarely found | ||
== Diagnosis == | == Diagnosis == | ||
*Easy bruising or bleeding out of proportion to the history of trauma | |||
*Recurrent bleeding into joints and muscles | *Easy bruising or bleeding out of proportion to the history of trauma | ||
*Recurrent bleeding into joints and muscles | |||
*Prolonged PTT; normal PT | *Prolonged PTT; normal PT | ||
== Work-Up == | == Work-Up == | ||
*Coags | |||
**Only helpful for making the dx; once established unlikely to yield new information | *Coags | ||
**PT - normal | **Only helpful for making the dx; once established unlikely to yield new information | ||
**PTT - abnormal (unless mild hemophilia) | **PT - normal | ||
*Head CT | **PTT - abnormal (unless mild hemophilia) | ||
**If c/o HA, AMS, significant blunt head injury | *Head CT | ||
*CT A/P | **If c/o HA, AMS, significant blunt head injury | ||
*CT A/P | |||
**Back, thigh, groin, or abd pain | **Back, thigh, groin, or abd pain | ||
== Treatment == | == Treatment == | ||
===Factor Replacement=== | |||
*FFP if | === Factor Replacement === | ||
**Each bag raises factor levels by 3-5% | |||
*Factor replacement if | *FFP if diagnosis is unknown (contains VIII and IX) | ||
**Dose of Factor VIII = weight (kg) x % increased desired x 0.5 | **Each bag raises factor levels by 3-5% | ||
***After initial correction give half this dose q8-12hr | *Factor replacement if diagnosis is known | ||
***1 IU/kg will increase the plasma concentration by 2% | **Dose of Factor VIII = weight (kg) x % increased desired x 0.5 | ||
**Dose of Factor IX = weight (kg) x % increase desired | ***After initial correction give half this dose q8-12hr | ||
***After initial correction give half this dose 24 hr later | ***1 IU/kg will increase the plasma concentration by 2% | ||
**Dose of Factor IX = weight (kg) x % increase desired | |||
***After initial correction give half this dose 24 hr later | |||
***1 IU/kg will increase the plasma concentration by 1% | ***1 IU/kg will increase the plasma concentration by 1% | ||
=== Specific Therapy === | === Specific Therapy (Factor VIII) === | ||
{| border="1" cellpadding="2" | {| border="1" cellpadding="2" | ||
|- | |- | ||
! align="left" | TYPE OF BLEEDING | ! align="left" | TYPE OF BLEEDING | ||
! align="left" | INITIAL DOSAGE | ! align="left" | INITIAL DOSAGE | ||
! align="left" | DURATION | ! align="left" | DURATION | ||
! align="left" | COMMENT | ! align="left" | COMMENT | ||
|- | |- | ||
| colspan="4" align="left" | ''' | | colspan="4" align="left" | '''SKIN''' | ||
|- | |- | ||
| align="left" | Abrasion | | align="left" | Abrasion | ||
| align="left" | None | | align="left" | None | ||
| align="left" | None | | align="left" | None | ||
| align="left" | Treat with local pressure and topical thrombin | | align="left" | Treat with local pressure and topical thrombin | ||
|- | |- | ||
| align="left" | Laceration | | align="left" | Laceration | ||
| align="left" | Usually none; if necessary, treat as minor | | align="left" | Usually none; if necessary, treat as minor | ||
| align="left" | None | | align="left" | None | ||
| align="left" | Local pressure and anesthetic with epinephrine may benefit; watch 4 hours after suturing; reexamine in 24 hours | | align="left" | Local pressure and anesthetic with epinephrine may benefit; watch 4 hours after suturing; reexamine in 24 hours | ||
|- | |- | ||
| align="left" | | | align="left" | <br> | ||
| align="left" | <br | | align="left" | <br> | ||
| align="left" | <br | | align="left" | <br> | ||
| align="left" | <br | | align="left" | <br> | ||
|- | |- | ||
| align="left" | Deep | | align="left" | Deep | ||
| align="left" | Minor bleeding (12.5 mg/kg) | | align="left" | Minor bleeding (12.5 mg/kg) | ||
| align="left" | Single-dose coverage | | align="left" | Single-dose coverage | ||
| align="left" | May need hospitalization for observation; repeat may be necessary for suture removal | | align="left" | May need hospitalization for observation; repeat may be necessary for suture removal | ||
|- | |- | ||
| align="left" | | | align="left" | '''EPISTAXIS''' | ||
| align="left" | <br | | align="left" | <br> | ||
| align="left" | <br | | align="left" | <br> | ||
| align="left" | <br | | align="left" | <br> | ||
|- | |- | ||
| align="left" | Spontaneous | | align="left" | Spontaneous | ||
| align="left" | Usually none; may need to be treated as mild bleeding | | align="left" | Usually none; may need to be treated as mild bleeding | ||
| align="left" | None | | align="left" | None | ||
| align="left" | Uncommon; consider platelet inhibition; treat in usual manner | | align="left" | Uncommon; consider platelet inhibition; treat in usual manner | ||
|- | |- | ||
| align="left" | Traumatic | | align="left" | Traumatic | ||
| align="left" | Moderate bleeding (25 mg/kg) | | align="left" | Moderate bleeding (25 mg/kg) | ||
| align="left" | Up to 5–7 days | | align="left" | Up to 5–7 days | ||
| align="left" | Trauma-related bleeding can be significant | | align="left" | Trauma-related bleeding can be significant | ||
|- | |- | ||
| colspan="4" align="left" | ''' | | colspan="4" align="left" | '''ORAL''' | ||
|- | |- | ||
| align="left" | Mucosa or tongue bites | | align="left" | Mucosa or tongue bites | ||
| align="left" | Usually none; treat as minor if persists | | align="left" | Usually none; treat as minor if persists | ||
| align="left" | Single dose | | align="left" | Single dose | ||
| align="left" | Commonly seen | | align="left" | Commonly seen | ||
|- | |- | ||
| align="left" | Traumatic (laceration) or dental extraction | | align="left" | Traumatic (laceration) or dental extraction | ||
| align="left" | Moderate (25 U/kg) to severe (50 U/kg) | | align="left" | Moderate (25 U/kg) to severe (50 U/kg) | ||
| align="left" | Single dose; may need more | | align="left" | Single dose; may need more | ||
| align="left" | Saliva rich in fibrin lytic activity; oral ε-aminocaproic acid (Amicar) may be given at 100 mg every 6 hr for 7 days to block fibrinolysis; check contraindications; hospitalize patients with severe bleeding | | align="left" | Saliva rich in fibrin lytic activity; oral ε-aminocaproic acid (Amicar) may be given at 100 mg every 6 hr for 7 days to block fibrinolysis; check contraindications; hospitalize patients with severe bleeding | ||
|- | |- | ||
| align="left" | '''Soft tissue/muscle hematomas''' | | align="left" | '''Soft tissue/muscle hematomas''' | ||
| align="left" | Moderate (25 U/kg) to severe (50 U/kg) | | align="left" | Moderate (25 U/kg) to severe (50 U/kg) | ||
| align="left" | 2–5 days | | align="left" | 2–5 days | ||
| align="left" | May be complicated by local pressure on nerves or vessels (e.g., iliopsoas, forearm, calf) | | align="left" | May be complicated by local pressure on nerves or vessels (e.g., iliopsoas, forearm, calf) | ||
|- | |- | ||
| colspan="4" align="left" | '''Hemarthrosis''' | | colspan="4" align="left" | '''Hemarthrosis''' | ||
|- | |- | ||
| align="left" | Early | | align="left" | Early | ||
| align="left" | Mild (12.5 U/kg) | | align="left" | Mild (12.5 U/kg) | ||
| align="left" | Single dose | | align="left" | Single dose | ||
| align="left" | Treat as earliest symptom (pain); knee, elbow, ankle more common | | align="left" | Treat as earliest symptom (pain); knee, elbow, ankle more common | ||
|- | |- | ||
| align="left" | Late or unresponsive cases of early hemarthrosis | | align="left" | Late or unresponsive cases of early hemarthrosis | ||
| align="left" | Mild to moderate (25 U/kg) | | align="left" | Mild to moderate (25 U/kg) | ||
| align="left" | 3–4 days | | align="left" | 3–4 days | ||
| align="left" | Arthrocentesis rarely necessary and only with 50% level coverage; immobilization is critical point of therapy | | align="left" | Arthrocentesis rarely necessary and only with 50% level coverage; immobilization is critical point of therapy | ||
|- | |- | ||
| align="left" | '''Hematuria''' | | align="left" | '''Hematuria''' | ||
| align="left" | Mild (12.5 U/kg) | | align="left" | Mild (12.5 U/kg) | ||
| align="left" | 2–3 days | | align="left" | 2–3 days | ||
| align="left" | Urokinase, the fibrinolytic enzyme, is in urine; with persistent hematuria an organic cause should be ruled out | | align="left" | Urokinase, the fibrinolytic enzyme, is in urine; with persistent hematuria an organic cause should be ruled out | ||
|- | |- | ||
| align="left" | Major | | align="left" | '''Major Bleeding''' | ||
| align="left" | Major bleeding (50 U/kg) | | align="left" | Major bleeding (50 U/kg) | ||
| align="left" | 7–10 days or 3–5 days after bleeding ceases | | align="left" | 7–10 days or 3–5 days after bleeding ceases | ||
| align="left" | In head trauma, therapy should be given prophylactically; early CT scan of head recommended for all | | align="left" | In head trauma, therapy should be given prophylactically; early CT scan of head recommended for all | ||
|} | |} | ||
== Source == | == Source == | ||
*Tintinalli | |||
*Rosen's <br> | |||
[[Category:Heme/Onc]] | [[Category:Heme/Onc]] | ||
Revision as of 02:35, 13 October 2011
Background
- Two types (clinically indistinguishable):
- Hemophilia A: Factor VIII deficiency
- Hemophilia B: Factor IX deficiency
- Substantial proportion of both types arise from spontaneous mutations
- X-linked disorders (overwhelmingly a disease of men)
- ICH is most common cause of hemorrhagic death
- Do not give NSAIDs or IM injections
- Avoid invasive procedures (e.g. central lines, LP (unless give factor replacement therapy))
- Consult hematology if pt has h/o inhibitors
Clinical Features
- Hemarthroses
- Leads to joint destruction and chronic arthropathy if not adequately treated
- Pts can reliably report when bleeding is occurring
- Hematomas
- Bleeding into soft tissues or muscle
- Neck (airway compromise)
- Limbs (compartment syndromes)
- Eye (retro-orbital hematoma)
- Spine (epidural hematoma)
- Retroperitoneum (iliopsoas bleeds and massive blood loss)
- Bleeding into soft tissues or muscle
- Mucocutaneous bleeding
- Spontaneous bleeding uncommon from oropharynx, GI tract, epistaxis, or hemoptysis
- CNS
- Intracranial bleeding is most common cause of hemorrhagic death
- Subdural hematomas occur spontaneously or with minimal trauma
- Hematuria
- Common, usually not serious, source is rarely found
Diagnosis
- Easy bruising or bleeding out of proportion to the history of trauma
- Recurrent bleeding into joints and muscles
- Prolonged PTT; normal PT
Work-Up
- Coags
- Only helpful for making the dx; once established unlikely to yield new information
- PT - normal
- PTT - abnormal (unless mild hemophilia)
- Head CT
- If c/o HA, AMS, significant blunt head injury
- CT A/P
- Back, thigh, groin, or abd pain
Treatment
Factor Replacement
- FFP if diagnosis is unknown (contains VIII and IX)
- Each bag raises factor levels by 3-5%
- Factor replacement if diagnosis is known
- Dose of Factor VIII = weight (kg) x % increased desired x 0.5
- After initial correction give half this dose q8-12hr
- 1 IU/kg will increase the plasma concentration by 2%
- Dose of Factor IX = weight (kg) x % increase desired
- After initial correction give half this dose 24 hr later
- 1 IU/kg will increase the plasma concentration by 1%
- Dose of Factor VIII = weight (kg) x % increased desired x 0.5
Specific Therapy (Factor VIII)
| TYPE OF BLEEDING | INITIAL DOSAGE | DURATION | COMMENT |
|---|---|---|---|
| SKIN | |||
| Abrasion | None | None | Treat with local pressure and topical thrombin |
| Laceration | Usually none; if necessary, treat as minor | None | Local pressure and anesthetic with epinephrine may benefit; watch 4 hours after suturing; reexamine in 24 hours |
| Deep | Minor bleeding (12.5 mg/kg) | Single-dose coverage | May need hospitalization for observation; repeat may be necessary for suture removal |
| EPISTAXIS | |||
| Spontaneous | Usually none; may need to be treated as mild bleeding | None | Uncommon; consider platelet inhibition; treat in usual manner |
| Traumatic | Moderate bleeding (25 mg/kg) | Up to 5–7 days | Trauma-related bleeding can be significant |
| ORAL | |||
| Mucosa or tongue bites | Usually none; treat as minor if persists | Single dose | Commonly seen |
| Traumatic (laceration) or dental extraction | Moderate (25 U/kg) to severe (50 U/kg) | Single dose; may need more | Saliva rich in fibrin lytic activity; oral ε-aminocaproic acid (Amicar) may be given at 100 mg every 6 hr for 7 days to block fibrinolysis; check contraindications; hospitalize patients with severe bleeding |
| Soft tissue/muscle hematomas | Moderate (25 U/kg) to severe (50 U/kg) | 2–5 days | May be complicated by local pressure on nerves or vessels (e.g., iliopsoas, forearm, calf) |
| Hemarthrosis | |||
| Early | Mild (12.5 U/kg) | Single dose | Treat as earliest symptom (pain); knee, elbow, ankle more common |
| Late or unresponsive cases of early hemarthrosis | Mild to moderate (25 U/kg) | 3–4 days | Arthrocentesis rarely necessary and only with 50% level coverage; immobilization is critical point of therapy |
| Hematuria | Mild (12.5 U/kg) | 2–3 days | Urokinase, the fibrinolytic enzyme, is in urine; with persistent hematuria an organic cause should be ruled out |
| Major Bleeding | Major bleeding (50 U/kg) | 7–10 days or 3–5 days after bleeding ceases | In head trauma, therapy should be given prophylactically; early CT scan of head recommended for all |
Source
- Tintinalli
- Rosen's
